Biogen Inc

Symbol: 0R1B.L

LSE

220.98

USD

Market price today

  • 27.5773

    P/E Ratio

  • 0.4723

    PEG Ratio

  • 32.12B

    MRK Cap

  • 0.00%

    DIV Yield

Biogen Inc (0R1B-L) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.68%

Operating Profit Margin

0.17%

Net Profit Margin

0.12%

Return on Assets

0.04%

Return on Equity

0.08%

Return on Capital Employed

0.07%

Company general description and statistics

Sector: Healthcare
Industry: Medical - Pharmaceuticals
CEO:Mr. Michel Vounatsos
Full-time employees:7400
City:Cambridge
Address:225 Binney St
IPO:1991-09-17
CIK:

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 7,800 full-time employees. The firm focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The firm markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). The company also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The firm's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.

General Outlook

When we look at how much money they make before expenses, they keep 0.678% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.173%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.123%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.043% return, is a testament to Biogen Inc's adeptness in optimizing resource deployment. Biogen Inc's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.081%. Furthermore, the proficiency of Biogen Inc in capital utilization is underscored by a remarkable 0.070% return on capital employed.

Stock Prices

Biogen Inc's stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $217.97, while its low point bottomed out at $214.71. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Biogen Inc's stock market.

Liquidity Ratios

Analyzing 0R1B.L liquidity ratios reveals its financial health of the firm. The current ratio of 199.73% gauges short-term asset coverage for liabilities. The quick ratio (91.72%) assesses immediate liquidity, while the cash ratio (30.57%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio199.73%
Quick Ratio91.72%
Cash Ratio30.57%

Profitability Ratios

0R1B.L profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 13.77% underscores its earnings before tax deductions. The effective tax rate stands at 10.43%, revealing its tax efficiency. The net income per EBT, 89.54%, and the EBT per EBIT, 79.49%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 17.32%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin13.77%
Effective Tax Rate10.43%
Net Income per EBT89.54%
EBT per EBIT79.49%
EBIT per Revenue17.32%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 2.00, it details the span from stock purchase to revenue. The 1 days it takes to settle debts showcases its creditor relations.

cards.indicatorcards.value
Days of Sales Outstanding92
Days of Inventory Outstanding305
Operating Cycle386.03
Days of Payables Outstanding49
Cash Conversion Cycle337
Receivables Turnover4.48
Payables Turnover7.51
Inventory Turnover1.20
Fixed Asset Turnover2.52
Asset Turnover0.35

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 10.68, and free cash flow per share, -39.27, depict cash generation on a per-share basis. The cash per share value, 7.25, showcases liquidity position. Lastly, the operating cash flow sales ratio, 0.16, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share10.68
Free Cash Flow per Share-39.27
Cash per Share7.25
Operating Cash Flow Sales Ratio0.16
Free Cash Flow to Operating Cash Flow Ratio-3.68
Cash Flow Coverage Ratio0.22
Short Term Coverage Ratio6.44
Capital Expenditure Coverage Ratio0.21
Dividend Paid and Capex Coverage Ratio0.21

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 26.18%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.47, we discern the balance between debt and equity financing. The long-term debt to capitalization, 31.44%, and total debt to capitalization, 32.20%, ratios shed light on its capital structure. An interest coverage of 6.61 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio26.18%
Debt Equity Ratio0.47
Long Term Debt to Capitalization31.44%
Total Debt to Capitalization32.20%
Interest Coverage6.61
Cash Flow to Debt Ratio0.22
Company Equity Multiplier1.81

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 65.08, provides a glimpse into top-line earnings distributed across each share. Net income per share, 8.02, reflects the portion of profit attributed to each share. The book value per share, 102.28, represents the net asset value distributed per share, while the tangible book value per share, 59.30, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share65.08
Net Income Per Share8.02
Book Value Per Share102.28
Tangible Book Value Per Share59.30
Shareholders Equity Per Share102.28
Interest Debt Per Share50.43
Capex Per Share-50.02

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, -0.17%, indicates top-line expansion, while the gross profit growth, -3.73%, reveals profitability trends. EBIT growth, -28.27%, and operating income growth, -28.27%, offer insights into operational profitability progression. The net income growth, -61.89%, showcases bottom-line expansion, and the EPS growth, -61.75%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth-0.17%
Gross Profit Growth-3.73%
EBIT Growth-28.27%
Operating Income Growth-28.27%
Net Income Growth-61.89%
EPS Growth-61.75%
EPS Diluted Growth-61.81%
Weighted Average Shares Growth-0.41%
Weighted Average Shares Diluted Growth-0.27%
Operating Cash Flow Growth11.77%
Free Cash Flow Growth-598.67%
10-Year Revenue Growth per Share123.72%
5-Year Revenue Growth per Share-0.68%
3-Year Revenue Growth per Share-15.25%
10-Year Operating CF Growth per Share8.65%
5-Year Operating CF Growth per Share-64.52%
3-Year Operating CF Growth per Share-59.33%
10-Year Net Income Growth per Share2.68%
5-Year Net Income Growth per Share-62.82%
3-Year Net Income Growth per Share-67.73%
10-Year Shareholders Equity Growth per Share182.74%
5-Year Shareholders Equity Growth per Share61.03%
3-Year Shareholders Equity Growth per Share53.79%
Receivables Growth-1.70%
Inventory Growth87.99%
Asset Growth9.33%
Book Value per Share Growth10.92%
Debt Growth10.69%
R&D Expense Growth12.72%
SGA Expenses Growth6.08%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 43,688,048,000, captures the company's total value, considering both debt and equity. Income quality, 1.33, assesses the reliability of reported earnings. The ratio of intangibles to total assets, 23.17%, indicates the value of non-physical assets, and capex to operating cash flow, -467.78%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value43,688,048,000
Income Quality1.33
Research and Development to Revenue23.44%
Intangibles to Total Assets23.17%
Capex to Operating Cash Flow-467.78%
Capex to Revenue-76.86%
Capex to Depreciation-1462.71%
Stock-Based Compensation to Revenue-11.30%
Graham Number135.89
Return on Tangible Assets5.63%
Graham Net Net-56.37
Working Capital3,425,000,000
Tangible Asset Value8,580,200,000
Net Current Asset Value-5,186,100,000
Average Receivables2,118,200,000
Average Payables447,400,000
Average Inventory1,935,900,000
Days Sales Outstanding81
Days Payables Outstanding49
Days of Inventory On Hand305
ROIC6.69%
ROE0.08%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 2.16, and the price to book ratio, 2.16, reflect the market's valuation relative to the company's book value. The price to sales ratio, 3.41, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -5.65, and price to operating cash flows, 20.70, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio2.16
Price to Book Ratio2.16
Price to Sales Ratio3.41
Price Cash Flow Ratio20.70
Price Earnings to Growth Ratio0.47
Enterprise Value Multiple12.11
Price Fair Value2.16
Price to Operating Cash Flow Ratio20.70
Price to Free Cash Flows Ratio-5.65
Price to Tangible Book Ratio2.52
Enterprise Value to Sales4.64
Enterprise Value Over EBITDA20.55
EV to Operating Cash Flow28.24
Earnings Yield3.11%
Free Cash Flow Yield-15.25%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Biogen Inc (0R1B.L) on the LSE in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 27.577 in 2024.

What is the ticker symbol of Biogen Inc stock?

The ticker symbol of Biogen Inc stock is 0R1B.L.

What is company IPO date?

IPO date of Biogen Inc is 1991-09-17.

What is company current share price?

Current share price is 220.980 USD.

What is stock market cap today?

The market cap of stock today is 32121873780.000.

What is PEG ratio in 2024?

The current 0.472 is 0.472 in 2024.

What is the number of employees in 2024?

In 2024 the company has 7400.